RZLT news

Rezolute reports Q1 FY27 financial results and business update. Enrollment is complete for the Phase 3 upsLIFT study with topline results expected in December, while the FDA recommended filing a BLA for congenital HI.

Rezolute has fully enrolled its Phase 3 upLIFT study for tumor hyperinsulinism, with topline data expected in mid-December. The open-label trial targets a response rate of at least 50% in refractory patients.

Rezolute released late FY26 results and positive interim onLIFT trial data, though the congenital HI program missed its primary endpoint, the company stated trial results remain under FDA review.

Rezolute reported interim data from its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism, with 6 of 8 enrolled participants meeting the primary endpoint of 50% reduction in glucose requirements. Topline results are expected in H2 2026, potentially supporting a regulatory pathway for this u…